La inhibicion de los puntos de control inmunologico, una terapia en evolucion: remembranza del Premio Nobel de Medicina 2018

Translated title of the contribution: Immune checkpoint inhibitors. A breakthrough in cancer therapy

Areli M. Cardenas-Oyarzo, Pamela A. Bocchieri-Oyarce, Cristian R. Mendez-Laport, Juan M. Zolezzi, Juvenal A. Rios*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Professors James P. Allison and Tasuku Honjo were awarded with the 2018 Nobel Prize in Medicine for their contributions in cancer immunotherapy. The latter is a breakthrough in cancer therapy, aimed to overcome tumor- induced immunosuppression, leading to the reactivation of the immune system against cancer cells. Under physiological conditions, the CTLA-4 and PD-1 proteins expressed on T-cells and discovered by the awarded scientists, lead to immune tolerance. Cancer cells exploit these control points to enhance the inhibition of T-cells. The expression of PD ligands (PD-L1) in tumor cells and CTLA-4 ligands in antigen presenting cells, which bind the PD-1 receptor and CTLA-4 respectively, block anti-tumor immunity. This situation led to a biotechnological race focused on the development of effective antibodies able to "turn-on" the immune system cheated by the tumor. Anti-CTLA-4 and anti-PD-1 antibodies improve life-expectancy in cancer patients. In this review, we perform an historical overview of Professors Allison and Honjo contribution, as well as the immunological basis of this new and powerful therapeutic strategy, highlighting the clinical benefits of such intervention.

Translated title of the contributionImmune checkpoint inhibitors. A breakthrough in cancer therapy
Original languageSpanish
Pages (from-to)93-99
Number of pages7
JournalRevista Medica de Chile
Volume150
Issue number1
DOIs
StatePublished - 2022

Bibliographical note

Publisher Copyright:
© 2022 Sociedad Medica de Santiago. All rights reserved.

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Immune checkpoint inhibitors. A breakthrough in cancer therapy: remembranza del Premio Nobel de Medicina 2018'. Together they form a unique fingerprint.

Cite this